New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
09:09 EDTAGENAgenus announces 'promising' Prophage G-200 Phase 2 results
Agenus announced that Phase 2 results of Prophage G-200 vaccine in recurrent patients with glioblastoma multiforme were hailed as "exciting" and a "very promising therapy" in an editorial published in Neuro-Oncology. The results of Agenusí Prophage vaccine Phase 2 study, published last month in Neuro-Oncology, demonstrated that more than 90% of the patients treated with the vaccine candidate were alive at six months. The median overall survival in these patients was approximately 11 months. The results of the Phase 2 trial have garnered the support of the National Cancer Institute. The study is actively enrolling and will offer the opportunity to provide important data to validate assessments of biomarkers and imaging criteria.
News For AGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
10:04 EDTAGENHigh option volume stocks
High option volume stocks: MTZ LQD LBTYA AGEN OCR CVC NTAP BBY BRKR VOC
08:56 EDTAGENAgenus 11M share Spot Secondary priced at $6.30
Jefferies and William Blair acted as joint book running managers for the offering.
May 20, 2015
16:01 EDTAGENAgenus files to sell common stock
Subscribe for More Information
May 14, 2015
07:10 EDTAGENAgenus announces presentation at ASCO highlighting Phase 2 Prophage data
Subscribe for More Information
May 13, 2015
13:41 EDTAGENAgenus to host research and development day
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use